← All trials
NCT01439191
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2005
- Primary completion
- Feb 1, 2007
- Completion date
- May 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 109
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Shanghai CP Guojian Pharmaceutical Co.,Ltd.Lead sponsor
- Fudan UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesStudy chair
- People's Liberation Army of ChinaOverall official - principal investigator
- Chinese Academy of Medical SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.